2-氯-4-氟-(9ci)-1H-苯并咪唑 | 256519-11-6

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-氯-4-氟-(9ci)-1H-苯并咪唑
• 中文别名: 2-氯-4-氟-(9CI)-1H-苯并咪唑
• 英文名称: 2-chloro-4-fluoro-1H-benzo[d]imidazole
• 英文别名: 2-chloro-4-fluoro-1H-benzimidazole
• CAS: 256519-11-6
• 化学式: C₇H₄ClFN₂
• 分子量: 170.574
• InChiKey: ZFSLVIPTTSYCLG-UHFFFAOYSA-N

物化性质

• 沸点：
  332.9±34.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  2

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-fluoro-1H-benzo[d]imidazole
Synonyms: 2-Chloro-4-fluorobenzimidazole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-fluoro-1H-benzo[d]imidazole
CAS number: 256519-11-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H4ClFN2
Molecular weight: 170.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

2-氯-4-氟-(9CI)-1H-苯并咪唑可用于制备两种化合物：4-氟-N-甲基-1-{4-[(3R)-3-甲基吗啉-4-基]-6-[1-((R)-S-甲基磺酰亚氨基)环丙基]嘧啶-2-基}-1H-苯并咪唑-2-胺和4-氟-N-甲基-1-{4-[(3R)-3-甲基吗啉-4-基]-6-[1-((S)-S-甲基磺酰亚氨基)环丙基]嘧啶-2-基}-1H-苯并咪唑-2-胺。这两种化合物在治疗增生性疾病（例如癌症），尤其是由共济失调-毛细血管扩张突变及RAD-3相关蛋白激酶抑制剂（通常称作ATR）介导的疾病中具有重要用途。

用途

2-氯-4-氟-(9CI)-1H-苯并咪唑是一种医药中间体，可通过将3-氟苯-1,2-二胺制备为4-氟-1H-苯并[d]咪唑-2(3H)-酮，再进行氯代得到。有文献报道其可用于制备ATR激酶抑制剂。

反应信息

• 作为反应物：
  描述：

  2-氯-4-氟-(9ci)-1H-苯并咪唑 、 甲胺 在 甲醇 、 氨 、 silica 、 二氯甲烷 作用下， 反应 16.0h， 以to afford 7-fluoro-N-methyl-1H-benzo[d]imidazol-2-amine (1.230 g, 75%)的产率得到(7-fluoro-1H-benzimidazol-2-yl)-methylamine
  参考文献：
  名称：

  Chemical compounds

  摘要：

  提供了式(I)的嘧啶基化合物，其中：R2为或其药学上可接受的盐，其制备过程，含有它们的制药组合物以及它们在治疗中的应用。

  公开号：

  US08999997B2
• 作为产物：
  描述：

  2,3-二氨基氟苯 在 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 2-氯-4-氟-(9ci)-1H-苯并咪唑
  参考文献：
  名称：

  CHEMICAL COMPOUNDS

  摘要：

  提供了化合物的化学式（I）， 其中： R 2 是吗 或其药用盐，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  US20110306613A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：MERCK SHARP & DOHME

  公开号：WO2014205592A1

  公开（公告）日：2014-12-31

  Compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system are disclosed.

  具有式（I）的化合物可用作乙型肝炎病毒（HCV）NS5B聚合酶抑制剂，公开了这类化合物的合成以及将这类化合物用于抑制HCV NS5B聚合酶活性、治疗或预防HCV感染以及在基于细胞的系统中抑制HCV病毒复制和/或病毒产生的用途。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：MERCK SHARP & DOHME

  公开号：WO2014209729A1

  公开（公告）日：2014-12-31

  The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)

  本发明涉及一种公式I的化合物，该化合物可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，以及该化合物的合成，以及利用该化合物抑制HCV NS5B聚合酶活性，用于治疗或预防HCV感染，以及在基于细胞的系统中抑制HCV病毒复制和/或病毒产生。
• FKBP inhibitors
  申请人：Pfizer Inc

  公开号：US06166011A1

  公开（公告）日：2000-12-26

  Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors. ##STR1##

  式(I)的化合物，其盐和溶剂化合物，其中取代基如本说明中所述，是FKBP抑制剂。
• [EN] MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY<br/>[FR] MORPHOLINOPYRIMIDINES ET LEUR UTILISATION EN THÉRAPIE
  申请人：ASTRAZENECA AB

  公开号：WO2011154737A1

  公开（公告）日：2011-12-15

  There is provided pyrimidinyl compounds of Formula (I), wherein R2 is (1) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了式(I)的嘧啶基化合物，其中R2为(1)或其药学上可接受的盐，其制备方法，含有它们的制药组合物以及它们在治疗中的应用。
• Chemical Compounds
  申请人：AstraZeneca AB

  公开号：US20150164908A1

  公开（公告）日：2015-06-18

  There is provided pyrimidinyl compounds of Formula (I), wherein: R 2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了式（I）的嘧啶基化合物，其中：R2是其药学上可接受的盐，其制备方法，包含它们的药物组合物以及它们在治疗中的用途。